Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

CHIEF FINANCIAL OFFICER

Executive Chairman

Chief Medical Officer

CHIEF EXECUTIVE OFFICER

Chief Financial Officer

Chief Business Officer

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development for the treatment or prevention of severe influenza. Further, the company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Sioux Falls, South Dakota.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibo...

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2023-12-07	Premium	bought	Premium	Premium	Premium	Chief Executive Officer
2023-11-30	Premium	bought	Premium	Premium	Premium	CHIEF FINANCIAL OFFICER
2023-11-29	Premium	bought	Premium	Premium	Premium	Executive Chairman
2023-11-24	Premium	acquired	Premium	Premium	Premium	-
2023-11-24	Premium	acquired	Premium	Premium	Premium	-
2023-11-24	Premium	acquired	Premium	Premium	Premium	-
2023-03-14	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2022-12-07	Premium	acquired	Premium	Premium	Premium	-
2022-12-07	Premium	acquired	Premium	Premium	Premium	-
2022-12-07	Premium	acquired	Premium	Premium	Premium	-
2022-09-13	Premium	bought	Premium	Premium	Premium	-
2022-09-07	Premium	bought	Premium	Premium	Premium	CHIEF EXECUTIVE OFFICER
2022-06-07	Premium	gifted	Premium	Premium	Premium	-
2022-06-06	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2022-05-20	Premium	acquired	Premium	Premium	Premium	-
2022-05-20	Premium	acquired	Premium	Premium	Premium	Executive Chairman
2022-05-20	Premium	sold	Premium	Premium	Premium	Executive Chairman
2021-10-26	Premium	sold	Premium	Premium	Premium	Chief Financial Officer
2021-10-25	Premium	acquired	Premium	Premium	Premium	Chief Financial Officer
2021-10-22	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2021-10-22	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2021-10-22	Premium	acquired	Premium	Premium	Premium	-
2021-10-22	Premium	acquired	Premium	Premium	Premium	-
2021-10-22	Premium	acquired	Premium	Premium	Premium	-
2021-10-22	Premium	acquired	Premium	Premium	Premium	-

SABS - SAB Biotherapeutics, Inc. Stock Price, Fair Value and News

Latest Insider Trading transactions for SABS